<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002871</url>
  </required_header>
  <id_info>
    <org_study_id>EczemaCT01</org_study_id>
    <secondary_id>CIV-13-08-011581</secondary_id>
    <nct_id>NCT02002871</nct_id>
  </id_info>
  <brief_title>Blue Light for Treating Eczema</brief_title>
  <official_title>Monocenter, Randomized, Intraindividual, Open Label, Exploratory Study Comparing 4 Weeks of Treatment With 453nm Blue Light With no Treatment in Patients With Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philips Light and Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philips Light and Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of
      treatment with 453nm blue light with no treatment in patients with Eczema. Patients will be
      screened up to 28 days before start of treatment. During the screening visit, the purpose and
      procedures of the study will be explained to potential patients and informed consent will be
      obtained. In addition, fungal superinfection of the target area will be examined using direct
      preparations and mycology cultures. At the baseline visit, patients with Eczema will be
      determined and all inclusion and exclusion criteria will be assessed. For eligible patients,
      two comparable treatment areas will be randomized to treatment with blue light (target area)
      or to serve as untreated control area. After randomization, patients will receive treatment
      of the target area with 3 applications per week at the investigational site for a total
      treatment period of 4 weeks. During those 4 weeks, safety and effectiveness assessments will
      be performed at weekly intervals. After end of treatment, the patients will be followed-up
      for another 2 weeks. In case no full resolution of adverse events occurred at the 2 week
      follow-up visit, a follow-up call will be performed after another 2 weeks. Treatment
      responses will be photo documented
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment</measure>
    <time_frame>at week 4</time_frame>
    <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up</measure>
    <time_frame>week 6</time_frame>
    <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area</measure>
    <time_frame>week 4, 6</time_frame>
    <description>Higher values describe higher erythema levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up</measure>
    <time_frame>week 6</time_frame>
    <description>Higher values describe a higher level of erythema.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area</measure>
    <time_frame>week 4, 6</time_frame>
    <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up</measure>
    <time_frame>week 6</time_frame>
    <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hyperpigmentation - Evaluation by Mexameter</measure>
    <time_frame>week 0, 2, 4, 6</time_frame>
    <description>Higher values describe a higher level of pigmentation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events (Serious and Non-serious)</measure>
    <time_frame>week 0, 2, 4, 6</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Device Events (Serious and Non-serious)</measure>
    <time_frame>over 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device Deficiencies</measure>
    <time_frame>over 6 weeks</time_frame>
    <description>This measure describes device deficiencies in general leading to a non functional device. No specific characteristics were assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recovery of Hyperpigmentation During Follow up Period (Compared to Last Treatment)</measure>
    <time_frame>week 6</time_frame>
    <description>Higher values describe a higher level of pigmentation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Acceptance of Hyperpigmentation at Week 6</measure>
    <time_frame>week 6</time_frame>
    <description>Questionaire if hyperpigmentation was acceptable if reported. Outcome was number of patients answering &quot;yes&quot; or &quot;no&quot;.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Blue light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>contralateral untreated control plaque on the same patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PSO-CT02 device</intervention_name>
    <description>The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.</description>
    <arm_group_label>Blue light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent prior to any study-mandated procedure

          2. Good health as determined by the Investigator according to physical examination

          3. Willing and able to comply with study requirements

          4. Skin type I-IV according to Fitzpatrick

          5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20

          6. Comparable clinical symptomatology of both intended treatment Areas

        8. Reliable method of contraception for women of childbearing potential (i.e. low failure
        rate less than 1% per year; e.g. oral contraceptives, intrauterine device [IUD] or
        transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure
        (e.g. sunbathe, solarium) during the course of the study

        Exclusion Criteria:

          1. Inmates of psychiatric wards, prisons, or other state institutions

          2. Investigator or any other team member involved in the conduct of the clinical study

          3. Participation in another clinical trial within the last 30 days

          4. Pregnant and lactating women

          5. Photodermatosis and/or Photosensitivity

          6. Porphyria and/or hypersensitivity to porphyrins

          7. Congenital or acquired immunodeficiency

          8. Patients with any of the following conditions present on the study areas; Malignoma of
             the skin or severe actinic damage of the skin, atypical naevi or signs of
             hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin,
             fungal and bacterial skin infections, parasitic infections and atrophic skin

          9. Patients with genetic deficiencies attached with increased sensitivity to light or
             increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome,
             Bloom- Syndrome)

         10. Current diagnosis of exfoliative or toxic dermatitis.

         11. Evidence of superinfection of the intended treatment areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Verena von Felbert, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik for Dermatology and Allergy, medical faculty of the RWTH Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik for Dermatology and Allergology, medical faculty of the RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>NRW</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <results_first_submitted>March 16, 2015</results_first_submitted>
  <results_first_submitted_qc>June 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2015</results_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eczema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first enrollment: 23.10.2013, University Clinic Aachen Date of LPLV: 17.02.2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Blue Light vs Control</title>
          <description>Light wavelength 453nm, compared to contralateral untreated control plaque on the same patient.
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Blue Light vs Control</title>
          <description>Light wavelength 453nm, compared to contralateral untreated control plaque on the same patient.
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment</title>
        <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
        <time_frame>at week 4</time_frame>
        <population>Overall number of participants is also 20 because control and treated plaque were anaylsed on the same patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment</title>
          <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
          <population>Overall number of participants is also 20 because control and treated plaque were anaylsed on the same patient.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.02"/>
                    <measurement group_id="O2" value="-1.3" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was performed on the difference of the change from baseline of the Blue light treated plaque versus the Control plaque.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up</title>
        <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up</title>
          <description>The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.54"/>
                    <measurement group_id="O2" value="-0.5" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area</title>
        <description>Higher values describe higher erythema levels.</description>
        <time_frame>week 4, 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area</title>
          <description>Higher values describe higher erythema levels.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="8.11"/>
                    <measurement group_id="O2" value="-0.9" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="7.74"/>
                    <measurement group_id="O2" value="0.3" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up</title>
        <description>Higher values describe a higher level of erythema.</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up</title>
          <description>Higher values describe a higher level of erythema.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="9.38"/>
                    <measurement group_id="O2" value="1.2" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area</title>
        <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching)</description>
        <time_frame>week 4, 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area</title>
          <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="20.72"/>
                    <measurement group_id="O2" value="-15.6" spread="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="26.25"/>
                    <measurement group_id="O2" value="-19.6" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up</title>
        <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching).</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up</title>
          <description>patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="14.11"/>
                    <measurement group_id="O2" value="-4.0" spread="14.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hyperpigmentation – Evaluation by Mexameter</title>
        <description>Higher values describe a higher level of pigmentation.</description>
        <time_frame>week 0, 2, 4, 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperpigmentation – Evaluation by Mexameter</title>
          <description>Higher values describe a higher level of pigmentation.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="6.85"/>
                    <measurement group_id="O2" value="28.0" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="6.01"/>
                    <measurement group_id="O2" value="28.4" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" spread="5.39"/>
                    <measurement group_id="O2" value="28.4" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" spread="6.57"/>
                    <measurement group_id="O2" value="26.8" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (Serious and Non-serious)</title>
        <time_frame>week 0, 2, 4, 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Serious and Non-serious)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Device Events (Serious and Non-serious)</title>
        <time_frame>over 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Device Events (Serious and Non-serious)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device Deficiencies</title>
        <description>This measure describes device deficiencies in general leading to a non functional device. No specific characteristics were assessed.</description>
        <time_frame>over 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Deficiencies</title>
          <description>This measure describes device deficiencies in general leading to a non functional device. No specific characteristics were assessed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Recovery of Hyperpigmentation During Follow up Period (Compared to Last Treatment)</title>
        <description>Higher values describe a higher level of pigmentation.</description>
        <time_frame>week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Contralateral untreated control plaque on the same patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery of Hyperpigmentation During Follow up Period (Compared to Last Treatment)</title>
          <description>Higher values describe a higher level of pigmentation.</description>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.78"/>
                    <measurement group_id="O2" value="-1.7" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Acceptance of Hyperpigmentation at Week 6</title>
        <description>Questionaire if hyperpigmentation was acceptable if reported. Outcome was number of patients answering &quot;yes&quot; or &quot;no&quot;.</description>
        <time_frame>week 6</time_frame>
        <population>7 patients out of 20 patients reported hyperpigmentation at week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Blue Light</title>
            <description>Light wavelength 453nm
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acceptance of Hyperpigmentation at Week 6</title>
          <description>Questionaire if hyperpigmentation was acceptable if reported. Outcome was number of patients answering &quot;yes&quot; or &quot;no&quot;.</description>
          <population>7 patients out of 20 patients reported hyperpigmentation at week 6.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the whole study period after the patients signed the informed consent untill the last follow up visit (week 0 to week 6)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Blue Light vs Control</title>
          <description>Light wavelength 453nm, compared to contralateral untreated control plaque on the same patient.
PSO-CT02 device: The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Matthias Born</name_or_title>
      <organization>Philips GmbH Innovative Technologies Aachen</organization>
      <phone>+491735321764</phone>
      <email>matthias.born@philips.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

